Selegiline raises the availability of this compound by selectively inhibiting MAO-B. This compound's second G protein-coupled receptor, which inhibits adenylyl cyclase, is targeted by many antipsychotic drugs. This compound's beta-hydroxylase catalyzes its transformation into norepinephrine. The ventral tegmental area contains the largest group of neurons releasing this neurotransmitter in the bra
Selegiline raises the availability of this compound by selectively inhibiting MAO-B. This compound's second G protein-coupled receptor, which inhibits adenylyl cyclase, is targeted by many antipsychotic drugs. This compound's beta-hydroxylase catalyzes its transformation into norepinephrine. The ventral tegmental area contains the largest group of neurons releasing this neurotransmitter in the brain. A chiral precursor to this compound with (*) L-configuration is used to treat a disease in which neurons releasing it in the substantia nigra die, leading to tremors and a slow, shuffling gait. For 10 points, name this neurotransmitter involved in pleasure-reward pathways in the brain, whose levels fall in Parkinson's disease.